Related Experiment Video
Updated: May 11, 2026
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
Anti-CTLA4 antibody therapy related complications on FDG PET/CT
Phillip J Koo1, William C Klingensmith, Karl D Lewis
1From the *Division of Nuclear Medicine, Department of Radiology, and †Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO.
Abstract:
Anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody therapy is a new class of drug which has demonstrated increased overall survival in patients with metastatic melanoma. Anti-CTLA-4 antibody therapy inhibits the CTLA-4 inhibitory signal, thereby enhancing the anti-tumor response of the cytotoxic T lymphocytes. This response can lead to a variety of immune-related adverse events. Many of these events are present on follow-up PET/CT examinations performed to assess response to therapy. It is important for the interpreting physician to be aware of the findings on PET/CT to avoid diagnosing adverse events as progressive disease and to alert clinicians regarding these complications.
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
